Merck, makers of Braveto, responds to the FDA’s notification to pet owners and veterinarians about potential neurological effects in dogs and cats treated with flea and tick drugs containing isoxazoline. Here is their official company response and then below it is a link to a fact sheet for more information on the topic.
“Merck Animal Health, the manufacturer of the Bravecto portfolio of products, remains confident in the safety and efficacy of Bravecto, which has been established through comprehensive clinical research in more than 170 studies. Nothing has changed about the Bravecto product.
The current FDA communication is based on information gathered on the isoxazoline class as a whole and therefore applies to all products in the class, which includes Bravecto.
- After over three years of surveillance of more than 80 million Bravecto doses distributed in 85 countries, the overall worldwide reporting rate for neurological signs, including seizures, remains classified as very rare. Very rare is defined by international regulatory authorities as less than 1 in 10,000 reported adverse events.
Every molecule is unique, even within a class, and each has its own safety profile. This is why it’s important for all pet owners to speak to their veterinarian before making a decision about flea and tick control products for their dog.
Nothing is more important to Merck Animal Health than the safety and efficacy of our products and the well-being of animals. We encourage all pet owners to speak to their veterinarian before making a decision about flea and tick control products. More than just a nuisance, fleas and ticks transmit disease and pose animal and human health risks. It is critical to protect pets from these parasites.”